Telix Pharmaceuticals Ltd has released a press release.
Appendix 4C and Activity Report March 2020 quarter
Filed with ASX ·
Watch Telix Pharmaceuticals' latest callTelix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20Read the transcript of Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call6ix hasn’t read this filing yet.
Telix Pharmaceuticals Limited on 6ix
Earlier from Telix Pharmaceuticals
- Commercial Distribution Agmt for Prostate Cancer Diagnostic
- Telix completes acquisition of licensed production facility
- Telix and partners receive 500k CRC research grant
- Positive FDA feedback on NDA submission process
- Appendix 4E - Summary of Results
Later from Telix Pharmaceuticals
- S&P DJI Announces June 2020 Quarterly Rebalance
- FDA grants breakthrough designation for TLX250-CDx product
- Receipt of $11.4M R&D tax rebate
- Appendix 4C and Activities Report - June 2020 quarter
- Report for half-year to 30 June 2020
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals